A Study of Avutometinib and Defactinib in People With Thyroid Cancer

NCT06007924 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Avutometinib
DRUG: Defactinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Verastem, Inc.